| Individual (0.1 mM) | DPPH | FRAP | ||||
| % RSA Real | % RSA Theoretical (Sum) | Type of Interaction | mgTE/mL | mgTE/mL Theoretical (Sum) | Type of Interaction | |
| A | 49.26a |
|
| 0.14a |
|
|
| B | 27.26b |
|
| 0.07b |
|
|
| C | 28.90b |
|
| 0.09b |
|
|
| D | 19.61c |
|
| 0.07b |
|
|
| E | 9.819d |
|
| 0.01c |
|
|
| Combination | % RSA Real | % RSA Theoretical (Sum) | Type of Interaction | mgTE/mL | mgTE/mL Theoretical (Sum) | Type of Interaction |
| AB | 90.04a | 76.53b | Synergic | 0.36a | 0.22b | Synergic |
| AC | 61.47b | 78.16a | Antagonist | 0.24a | 0.24a | Additive |
| AD | 52.56b | 68.87a | Antagonist | 0.23a | 0.22a | Additive |
| AE | 48.65b | 59.08a | Antagonist | 0.10b | 0.16a | Antagonist |
| BC | 45.76b | 56.17a | Antagonist | 0.17a | 0.17a | Additive |
| BD | 35.47b | 46.87a | Antagonist | 0.18a | 0.15b | Synergic |
| BE | 25.99b | 37.08a | Antagonist | 0.11a | 0.09a | Additive |
| CD | 31.34b | 48.51a | Antagonist | 0.18a | 0.17a | Additive |
| CE | 32.31b | 38.72a | Antagonist | 0.11a | 0.11a | Additive |